

Novabiochem® Letters 1^{Vol.} 15


Novabiochem®
30 Years of Innovation




New Building blocks for synthesis of difficult peptides

NEW • Cysteine pseudoproline dipeptides


Fmoc-Ala-Cys($\psi^{\text{Dmp,Hpro}}$)-OH




Fmoc-Leu-Cys($\psi^{\text{Dmp,Hpro}}$)-OH



Fmoc-Lys(Boc)-Cys($\psi^{\text{Dmp,Hpro}}$)-OH



Fmoc-Val-Cys($\psi^{\text{Dmp,Hpro}}$)-OH



Features & Benefits

- Pseudoproline dipeptides for cysteine-containing peptides
- Prevents aggregation and helps improve yield and purity of desired peptide
- Couples without epimerization of cysteine residue

Mutter's pseudoproline dipeptides [1] are extremely powerful tools for enhancing synthetic efficiency in Fmoc SPPS. They work by mimicking the natural propensity of proline [2, 3] to disrupt the formation of the secondary structures during peptide assembly. Their use leads to better and more predictable

acylation and deprotection kinetics, which results in higher purities and solubilities of crude products, easier HPLC purification and improved yields, with less need to repeat failed syntheses. They have proved particularly effective in the synthesis of intractable peptides [4 – 7], long peptides/small proteins [8 – 16], and cyclic peptides [17, 18], enabling in many cases the production of peptides that otherwise could not be made. Standard pseudoproline derivatives are only appropriate for use in Ser- or Thr-containing sequences as they consist of a dipeptide in which the Ser or Thr residue has been reversibly protected with acetone. Novabiochem is therefore pleased to offer cysteine-based pseudoproline dipeptides, to expand the scope of the structure breaking building blocks available for Fmoc SPPS.

These dipeptides are used in exactly the same manner as standard pseudoproline dipeptides. They can be coupled using any standard coupling method, such as PyBOP/DIPEA or DIPCDI/Oxyma Pure, substituting a Cys residue together with the preceding amino acid residue in the peptide sequence with the appropriate pseudoproline dipeptide (Figure 1). The thiazolidine ring is labile to TFA, so the native sequence cysteinyl-containing peptide is regenerated on cleavage and deprotection.




Fig. 1: Principles of using cysteinyl pseudoproline dipeptides.


The cysteine pseudoprolines can be used in combination with standard pseudoprolines and Dmb-dipeptides. Positioning of these structure-breaking derivatives approximately 6 residues apart in the peptide sequence at regular intervals has proven to be an extremely effective approach for the synthesis of long and amyloidogenic peptides. This approach has been exemplified by the synthesis of a 95 residue peptide in remarkable purity through the expeditious use of 7 pseudoproline dipeptides [8], in the synthesis of 101mer related to d2 domain of VEGF receptor [12], and parallel production of ubiquitin analogs [13].

Cat.No.	Product	Contents	Price
852381	Fmoc-Ala-Cys(ψ ^{Dmp,H} pro)-OH	1 g	POA
NEW		5 g	POA
852382	Fmoc-Leu-Cys(ψ ^{Dmp,H} pro)-OH	1 g	POA
NEW		5 g	POA
852383	Fmoc-Val-Cys(ψ ^{Dmp,H} pro)-OH	1 g	POA
NEW		5 g	POA
852384	Fmoc-Lys(Boc)-Cys(ψ ^{Dmp,H} pro)-OH	1 g	POA
NEW		5 g	POA
852175	Fmoc-Ala-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852180	Fmoc-Ala-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA


852185	Fmoc-Asn(Trt)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852183	Fmoc-Asn(Trt)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852186	Fmoc-Asp(OtBu)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852199	Fmoc-Asp(OtBu)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852190	Fmoc-Gln(Trt)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852198	Fmoc-Gln(Trt)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852177	Fmoc-Glu(OtBu)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852196	Fmoc-Glu(OtBu)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852200	Fmoc-Gly-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852197	Fmoc-Gly-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852194	Fmoc-Ile-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852193	Fmoc-Ile-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852179	Fmoc-Leu-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852184	Fmoc-Leu-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852178	Fmoc-Lys(Boc)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852191	Fmoc-Lys(Boc)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852195	Fmoc-Phe-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852201	Fmoc-Phe-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852187	Fmoc-Ser(tBu)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852192	Fmoc-Ser(tBu)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852202	Fmoc-Trp(Boc)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852188	Fmoc-Trp(Boc)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852189	Fmoc-Tyr(tBu)-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852182	Fmoc-Tyr(tBu)-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852176	Fmoc-Val-Ser(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA
852181	Fmoc-Val-Thr(ψ ^{Me,Me} pro)-OH	1 g	POA
		5 g	POA

NEW • Dmb-dipeptides


Fmoc-Glu(OtBu)-(Dmb)Gly-OH



Fmoc-Lys(Boc)-(Dmb)Gly-OH



Fmoc-Ser(tBu)-(Dmb)Gly-OH



Features & Benefits

- Helps prevent aggregation in glycine-containing peptides
- Use leads to improved yields and purity of desired peptide


Novabiochem is pleased to introduce three new Dmb-dipeptides derivatives [19, 20]: They work in exactly the same way and offer the same benefits as pseudoproline dipeptides i.e. faster and more predictable acylation reactions, higher yields and purities of crude products, and less failed syntheses. Using them is very straightforward, one simply substitutes a Gly residue together with the preceding amino acid residue in the peptide sequence with the appropriate dipeptide (Figure 3-15). The native sequence is regenerated on TFA-mediated cleavage and deprotection. For peptides containing the Asp-Gly motif, Fmoc-Asp(OtBu)-(Dmb)Gly-OH is highly recommended as its use for introduction of the Asp-Gly dipeptide completely prevents aspartimide formation [20].

Cat.No.	Product	Contents	Price
852405	Fmoc-Glu(OtBu)-(Dmb)Gly-OH	1 g	POA
NEW		5 g	POA
852407	Fmoc-Lys(Boc)-(Dmb)Gly-OH	1 g	POA
NEW		5 g	POA
852406	Fmoc-Ser(tBu)-(Dmb)Gly-OH	1 g	POA
NEW		5 g	POA
852108	Fmoc-Ala-(Dmb)Gly-OH	1 g	POA
		5 g	POA
852115	Fmoc-Asp(OtBu)-(Dmb)Gly-OH	1 g	POA
		5 g	POA
852109	Fmoc-Gly-(Dmb)Gly-OH	1 g	POA
		5 g	POA
852114	Fmoc-Ile-(Dmb)Gly-OH	1 g	POA
		5 g	POA
852114	Fmoc-Leu-(Dmb)Gly-OH	1 g	POA
		5 g	POA
852116	Fmoc-Val-(Dmb)Gly-OH	1 g	POA
		5 g	POA

New Resins for Fmoc SPPS

NEW • Resins for native chemical ligation

SEA-PS



Features & Benefits

- Generates a thioester surrogate for native chemical ligation

SEA-PS resin is a new tool for the synthesis of peptides for native chemical ligation (NCL) by Fmoc SPPS [21 – 23]. This resin on treatment with TFA cleavage generates peptides bearing a bis(2-sulfanylethyl)amide (SEA) on their C-terminus. These peptide at neutral pH exist as a mixture of amide and thioester forms. In presence of added thiol, the SEA group is cleaved to give the peptide thioester, which can be isolated or used *in situ* for NCL (Figure 2).

Loading of the resin with the C-terminal residue is best done using Fmoc-amino acid coupled activated with HATU. After peptide assembly, the peptide-SEA is cleaved from the resin using standard TFA cocktails. To stabilize the peptide and to simplify HPLC analysis and purification in acidic buffers, the SEA peptide should be converted to the disulfide form by air or iodine oxidation (Figure 5-12). In the presence of a reducing agent such as TCEP, peptide-SEA disulfides undergo rapid NCL or can be converted to thioesters. In the absence of a reducing reagent, peptide-SEA disulfides do not undergo ligation, which has been exploited to perform one-pot three segment ligations [24].





Fig. 2: SEA strategy [21-24].


Cat.No.	Product	Contents	Price
855152	SEA-PS	1 g	POA
NEW		5 g	POA

NEW • High swell PEG-PS resins

NovaSyn® TG^{XV} A resin



NovaSyn® TG^{XV} R resin



NovaSyn® TG^{XV} A and NovaSyn® TG^{XV} R resins are special formulations of NovaSyn® TGA and NovaSyn® TGR, with swelling properties comparable to Chemmatrix resins. They are therefore excellent tools for the synthesis of long and difficult peptides.

Cat.No.	Product	Contents	Price
855156 NEW	NovaSyn® TG ^{XV} A resin	1 g	POA
		5 g	POA
		25 g	POA
855155 NEW	NovaSyn® TG ^{XV} R resin	1 g	POA
		5 g	POA
		25 g	POA
855127	NovaSyn® TG ^R A resin	1 g	POA
		5 g	POA
855128	NovaSyn® TG ^R R resin	1 g	POA
		5 g	POA
855005	NovaSyn® TG A resin	1 g	POA
		5 g	POA
855009	NovaSyn® TG R resin	1 g	POA
		5 g	POA

References

1. a) T. Haack & M. Mutter (1992) *Tetrahedron Lett.*, **33**, 1589; b) M. Mutter, et al. (1995) *Pept. Res.*, **8**, 145.
2. a) C. Toniolo, et al. (1981) *Makromol. Chem.*, **182**, 1997; b) C. Toniolo, et al. (1981) *Makromol. Chem.*, **182**, 2007.
3. J. Bedford, et al. (1992) *Int. J. Peptide Protein Res.*, **40**, 300.
4. P. White, et al. in "Peptides 1998, Proc. of 25th European Peptide Symposium", Budapest, Akadémiai Kiadó, 1998, pp. 120.
5. C. Hyde, et al. (1994) *Int. J. Peptide Protein Res.*, **43**, 431.
6. R. von Eggelkraut-Gottanka, et al. (2003) *ChemBioChem*, **4**, 425.
7. F. Shabanpoor, et al. (2007) *J. Pept. Sci.*, **13**, 113.
8. a) P. White, et al. (2004) *J. Pept. Sci.*, **10**, 18; b) P. White, et al. (2003) *Biopolymers*, **71**, 338.
9. F. Garcia-Martin, et al. (2006) *Biopolymers*, **84**, 566.
10. S. Abu-Baker & G. A. Lorigan (2006) *Biochemistry*, **45**, 13312.
12. V. Goncalves, et al. (2009) *J. Pept. Sci.*, **15**, 417.
13. F. El Oualid, et al. (2010) *Angew. Chem. Int. Ed.*, **49**, 10149.
14. S. N. Bavikar, et al. (2012) *Angew. Chem. Int. Ed.*, **51**, 758.
15. P. Nagorny, et al. (2012) *Angew. Chem. Int. Ed.*, **51**, 975.
16. C. Yves-Marie, et al. (2010) *J. Pept. Sci.*, **16**, 98.
17. A. Ehrlich, et al. (1996) *J. Org. Chem.*, **61**, 8831.
18. N. Schmiedeberg & H. Kessler (2002) *Org. Lett.*, **4**, 59.
19. S. Zahariev, et al. (2005) *J. Pept. Sci.*, **11**, 17.
20. V. Cardona, et al. (2008) *Int. J. Pept. Res. Ther.*, **14**, 285.
21. N. Ollivier, et al. (2010) *Org. Lett.*, **12**, 5238.
22. J. Dheur, et al. (2011) *J. Org. Chem.*, **76**, 3194.
23. J. Dheur, et al. (2011) *Org. Lett.*, **13**, 1560.
24. N. Ollivier, et al. (2012) *Angew. Chem. Int. Ed.*, **51**, 209.

For more information please contact:

Merck KGaA
64271 Darmstadt, Germany
E-mail: contact@merckgroup.com
www.merckmillipore.com/peptides



www.merckmillipore.com/novabiochem

Product prices and availability are subject to change. Products are warranted only to meet the specifications set forth on their label/packaging and/or certificate of analysis at the time of shipment or for the expressly stated duration. NO OTHER WARRANTY WHETHER EXPRESS, IMPLIED OR BY OPERATION OF LAW IS GRANTED. The products are intended for research purposes only and are not to be used for drug or diagnostic purposes, or for human use. Merck KGaA's products may not be resold or used to manufacture commercial products without the prior written approval of Merck KGaA. All sales are subject to Merck KGaA's complete Terms and Conditions of Sale (or if sold through an affiliated company of Merck KGaA, such affiliated company's complete Terms and Conditions of Sale). NovaSyn® and Novabiochem® are registered trademarks of Merck KGaA in Australia, Germany, Japan, Switzerland, the United Kingdom, and the United States. SpheriTide® is a registered trademark of SpheriTech in the United Kingdom.
©Copyright 2015 Merck KGaA, Darmstadt, Germany. All rights reserved.